DNA methyltransferase 3 alpha mRNA (DNMT3A mRNA) (DNMT3A mRNA)

DNA methyltransferase 3 alpha (DNMT3A) mRNA is the messenger RNA transcript that encodes the DNMT3A enzyme, a critical de novo DNA methyltransferase responsible for establishing methylation patterns on cytosine residues in CpG dinucleotides (Source: UniProt Q9Y6K1). This epigenetic modification is essential for gene silencing, genomic imprinting, and proper cellular differentiation during development (Source: PubMed PMID: 22037309). In clinical oncology, DNMT3A is a major focus due to the high prevalence of somatic mutations, such as the R882 hotspot, in hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (Source: NIH/NCI). These mutations often lead to the production of dysfunctional or dominant-negative protein variants that drive leukemogenesis by altering the epigenetic landscape of hematopoietic stem cells. Targeting the DNMT3A mRNA directly using RNA-based modalities like small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs) represents a therapeutic strategy to selectively reduce the expression of these oncogenic transcripts (Source: PubMed PMID: 31515465). While promising, this approach must navigate challenges such as ensuring delivery to the bone marrow and avoiding systemic toxicity resulting from global DNA hypomethylation (Source: PubMed PMID: 24618899). Furthermore, the mRNA exists in multiple isoforms, such as DNMT3A1 and DNMT3A2, which may require specific targeting strategies depending on the tissue context (Source: PubMed PMID: 29109525).

Other names

DNA (cytosine-5)-methyltransferase 3A mRNADNMT3A transcriptDNMT3A1 mRNADNMT3A2 mRNA

RNA interference and antisense-mediated mRNA degradation